WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis.
Fernando Rodriguez-PerezDean E NatwickLauren SchiffDavid Trombley McSwiggenAlec HeckertMelina HueyHuntly MorrisonMandy LooRafael G MirandaJohn FilbinJose OrtegaKayla Van BurenDanny MurnockArnold TaoRenee ButlerKylie ChengWilliam TarvestadZhengjian ZhangEric GonzalezRand M MillerMarcus KellyYangzhong TangJaclyn J HoDaniel AndersonCharlene BashoreStephen BashamPublished in: Nature communications (2024)
Synthetic lethality provides an attractive strategy for developing targeted cancer therapies. For example, cancer cells with high levels of microsatellite instability (MSI-H) are dependent on the Werner (WRN) helicase for survival. However, the mechanisms that regulate WRN spatiotemporal dynamics remain poorly understood. Here, we used single-molecule tracking (SMT) in combination with a WRN inhibitor to examine WRN dynamics within the nuclei of living cancer cells. WRN inhibition traps the helicase on chromatin, requiring p97/VCP for extraction and proteasomal degradation in a MSI-H dependent manner. Using a phenotypic screen, we identify the PIAS4-RNF4 axis as the pathway responsible for WRN degradation. Finally, we show that co-inhibition of WRN and SUMOylation has an additive toxic effect in MSI-H cells and confirm the in vivo activity of WRN inhibition using an MSI-H mouse xenograft model. This work elucidates a regulatory mechanism for WRN that may facilitate identification of new therapeutic modalities, and highlights the use of SMT as a tool for drug discovery and mechanism-of-action studies.